Recombinant 2019-nCoV Papain-like Protease Protein (His Tag) | 763-PKSR030511

Recombinant 2019-nCoV Papain-like Protease Protein (His Tag) | PKSR030511 | Elabscience.

Synonym: Papain-like Protease; PLpro; PL-PRO; pp1a; Replicase polyprotein 1a

Activity: Measured by its ability to cleave a fluorogenic peptide substrate, Arg-Leu-Arg-Gly-Gly-AMC (RLRGGAMC) .The Specific Activity is >80pmols/min/μg

Protein Construction: A DNA sequence encoding the SARS-CoV-2 (2019-nCoV) papain-like protease (YP_009725299.1) (Glu1564-Val1880) was expressed with a polyhistidine tag at the N-terminus.

Sequence: Glu1564-Val1880

Fusion tag: N-6His

Accession: YP_009725299.1

Species: SARS-CoV-2

Expressed Host: E.coli

Shipping Conditions: This product is provided as lyophilized powder which is shipped with ice packs.

Purity: > 90 % as determined by reducing SDS-PAGE.

Endotoxin: < 1.0 EU per µg as determined by the LAL method.

Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Mol Mass: 36.79 kDa

AP Mol Mass: N/A

Formulation: Lyophilized from sterile 20 mM Tris 500mM NaCl, pH 7.4.

Reconstitution: Please refer to the printed manual for detailed information.

Background: The coronaviral proteases, papain-like protease (PLpro) and 3C-like protease (3CLpro) , are attractive antiviral drug targets because they are essential for coronaviral replication. PLpro has the additional function of stripping ubiquitin and ISG15 from host-cell proteins to aid coronaviruses in their evasion of the host innate immune responses. Targeting PLpro with antiviral drugs may have an advantage in not only inhibiting viral replication but also inhibiting the dysregulation of signaling cascades in infected cells that may lead to cell death in surrounding, uninfected cells.